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See Article, pages 234–240Anyone trying to understand the burden of disease of NAFLD in
our societies might feel like they are trapped in a labyrinth, under
a dim light. A labyrinth, because there are many ways to look for
NAFLD and not just one straightforward diagnostic method.
Under a dim light, because all these imperfect procedures and
tests do not allow us to see far enough, given their limited sensi-
tivity and speciﬁcity. Yet, for all these uncertainties, the sense of
facing a real problem is overwhelmingly present. Just as it should
be when you are trapped in a labyrinth.
Because of the absence of a simple and readily available mar-
ker of NAFLD, data from the general population has been slow to
emerge. The report from Armstrong et al. in this issue of the Jour-
nal of Hepatology is therefore an important addition to the litera-
ture. The authors studied NAFLD in the setting of a large, primary
care practice in the UK. This is a step closer to the general popu-
lation although not yet as close as screening for NAFLD in factory
workers [1] or through City Hall records [2]. The overall design
was to identify individuals with increased liver function tests,
but without a past history of liver disease, known alcohol-related
health problems, past or present intravenous drug use or current
symptoms of liver disease. Increased LFTs were therefore diag-
nosed in asymptomatic individuals with a low risk of liver dis-
ease. But this does not mean that those individuals were
otherwise healthy. Most of them had chronic health problems
which actually prompted testing for LFTs. In fact 40% of partici-
pating individuals were obese, 43% had arterial hypertension,
and 24% had type 2 diabetes (Table 2), all conditions epidemio-
logically associated with NAFLD. While this is far from the end-
of-spectrum seen in tertiary referral centers, it still concerns a
population enriched with risk factors for NAFLD, albeit less so
than reports from specialized academic centers. With these entry
criteria, 1118 individuals were included. The strength of the
study is that almost all of them underwent a thorough work-up
including ultrasound and specialized hepatological tests, to diag-
nose the underlying liver disease.
The results come as a surprise to anyone that ﬁrst learnedwhat
causes liver disease, a bare 20 years ago. In today’s clinical land-
scape, 26% of these cases are related to NAFLD, 25% to alcohol con-
sumption, and 45% have no clear cause, while all classical causes ofJournal of Hepatology 20
qDOI of original article: 10.1016/j.jhep.2011.03.020.
⇑ Corresponding author.
E-mail address: vratziu@teaser.fr (V. Ratziu).liver diseases (HCV and HBV infection, hemochromatosis, primary
biliary cirrhosis, alpha1 anti-trypsin deﬁciency, etc.) account for
less than 1% each! Thus, NAFLD is nowadays the main player in
hepatology and probably here to stay. Worse, considering how
the diagnosis was ascertained, there is a fair chance that the prev-
alence of NAFLD might have been underestimated by a good mar-
gin. Ultrasound is notoriously unable to diagnose excess fat in the
liver when this is less than 20–30% on liver biopsy. Thresholds for
alcohol were conservative at best (more than 20 g/day for females
and 30 g/day for males); this is in line with expert recommenda-
tions [3] but totally misses the epidemiological reality of a large
segment of the populationwhich is exposed to bothmetabolic risk
factors and moderate amounts of alcohol (<50 g/day). Studies in
the French general population have shown that almost two-thirds
of patients attending a routine examination in Social Security
Health Care centers have metabolic risk factors but also consume
alcohol higher than 10 g/day for females and 20 g/day for males
[4]. Because of their exposure to metabolic risk factors, there is
no reason why these individuals should not be considered as hav-
ing NAFLD (with or without alcoholic liver disease) until proven
otherwise. In some large epidemiological studies, only daily
amounts >30 g/day were associated with steatosis [5]. Note that
in the study by Armstrong et al., 87% of the subjects with alcoholic
liver disease (diagnosed with the liberal thresholds mentioned
above) also happened to be overweight. On the other hand, more
than half of these patients with ‘‘excessive’’ alcohol consumption
did not have steatosis detectable by ultrasound. Despite the insuf-
ﬁcient sensitivity/speciﬁcity of ultrasound, this questionswhether
the thresholds for the diagnosis of alcoholic liver disease might
have been too low. Unsurprisingly, older studies establishing asso-
ciations between alcohol intake and risk of alcoholic liver disease
did not adjust for BMI, diabetes, or other metabolic risk factors.
The lines are thus blurred until comprehensive studies of the asso-
ciation between exposure to metabolic risk factors and moderate
alcohol consumption vs. hard outcomes become available. Mean-
while, it is reasonable to assume that the prevalence of NAFLD in
asymptomatic patientswith altered LFTs and no suspicion of other
causes of chronic liver disease is even higher than that presented
by Armstrong et al.
To their credit, Armstrong et al. avoided to some extent the
usual limitations of this type of study. The vast majority of blood
samples (1029/1118) were assayed in a central lab and the
results of the others were standardized to the central lab refer-12 vol. 56 j 23–25
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ence range. The upper limit of normal was close to 40 IU/L, higher
than ideal but still acceptable and in line with that used by most
labs. Ultrasound was performed by senior radiologists with good
inter-observer reproducibility. Nonetheless, the study was based
on a single time-point instead of persistently elevated LFTs. Many
subjects with increases in aminotransferases could have normal
values upon retesting. This could be accounted for by transient
infectious episodes, drug intake, or other circumstantial events.
The proportion of cases with an unknown cause of altered LFTs
could have been lower, and that of cases due to NAFLD or alcohol
consumption higher than what was ultimately found by Arm-
strong et al. Interestingly, an increased level of serum gamma
glutamyl transpeptidase appeared to have higher sensitivity than
increased aminotransferases, the usual test for screening patients
at risk for NASH.
These high epidemiological numbers are backed up by a few
other converging reports. Earlier this year in a study performed
in middle-aged, US Army personnel seeking medical care for
unspeciﬁedmedical conditions (but unrelated toNAFLD), theprev-
alence of ultrasonographically deﬁned and histologically con-
ﬁrmed fatty liver was an intriguing 48% [6]. This is double the
previous estimates fromWestern countries based on similar ultra-
sound detection. It may be explained by particulars of the popula-
tion under study (mean BMI of 30 kg/m2 and a 45% prevalence of
obesity) but, remarkably and contrary to the report by Armstrong
et al., patients were included irrespective of abnormal LFT values.
Even more concerning are data of incidental ﬁndings of NAFLD
and NASH in candidates for living-donor liver transplantation.
Because of the selection process, these individuals are at lowest
risk for liver disease. Yet, histological veriﬁcation shows that the
prevalence of steatosis alone ranges from 12–51% and that of ste-
atohepatitis from 2% to 15% [7–12]. It should come as no surprise
that the initial reports in the 90’s [13] were largely conﬁrmed a
decade later: nowadays NAFLD has become the most frequent
cause of newly diagnosed cases of chronic liver disease [14].
While this study shows that NAFLD is exceedingly common in
today’s practice, it is also a reminder that all patients with
increased LFTs and no alcohol consumption do not, necessarily,
have NAFLD. In this series, 45% of patients with a single-time
increase in LFTs did not have an identiﬁable chronic liver disease,
including NAFLD. In another series of patients with persistently
elevated aminotransferases and no identiﬁable cause of liver dis-
ease, including alcohol consumption, only 55% had histologically
documented NAFLD [15]. Twenty percent had normal or near
normal liver biopsy and 25% had miscellaneous pathological con-
ditions that did not qualify for NAFLD. Population-based surveys
such as NHANES III asserting de facto that any patient with an
unexplained increase in ALT has NAFLD, thus most likely have
some signiﬁcant margin of error.
Granted that now everyone accepts NAFLD as the front-runner
in the epidemiology contest, the next question is: to what extent
does it induce signiﬁcant liver damage? Most available series,
heavily biased by tertiary-care referral, tend to overemphasize
the end-of-severity spectrum of the disease. The current report
by Armstrong et al., as well as the earlier report by Williams cited
above, provide some insights from a more global perspective, clo-
ser to the general population.
Two issues require consideration: (1) the frequency of NASH,
the progressive form of the disease and (2) the frequency of
advanced ﬁbrosis, including cirrhosis. When performing liver
biopsy in 134 unselected patients with ultrasound suggestive of24 Journal of Hepatology 20hepatic steatosis, Williams et al. showed that 30% of patients with
NAFLD (at least 12% of the entire adult population that was
screened) had NASH [6]. This is much higher than the conven-
tional estimate drawn from studies performed in the 80’s and
early 90’s, that showed that only 10% of patients with fatty liver
have steatohepatitis. A few other recent studies with liver histol-
ogy are rather in the high range found by Williams et al.: 43–55%
in patients with increased aminotransferases [15,16], and as high
as 49% in morbidly obese patients [17]. Considering that steato-
hepatitis is the main histological factor driving ﬁbrosis progres-
sion, this means that at least one-third of patients with NAFLD
are at risk of progressive disease. Howmany of these patients will
actually develop advanced ﬁbrosis depends on contingent factors,
not all related to NAFLD: length of follow-up, inter-individual
variability for susceptibility to ﬁbrosis and competing risks from
co-morbid associations. But the point here is that, even in unse-
lected populations, a signiﬁcant proportion of patients with
NAFLD are at risk of disease progression and thus should be mon-
itored and treated accordingly.
It might be argued that rather than counting the number of
patients at risk for progressive disease, a better estimate of the
potential severity of NAFLD would be the proportion of patients
that actually have advanced disease, i.e. signiﬁcant (bridging)
ﬁbrosis and cirrhosis. Armstrong et al. used a serum ﬁbrosis mar-
ker, the NAFLD ﬁbrosis score (NFS) [18], and found a high score,
suggestive of advanced ﬁbrosis, in almost 8% of patients with
NAFLD. The diagnostic performance of the NFS was conﬁrmed
vs. biopsy in a small series of patients [19] with an acceptable
but rather low positive predictive value for ruling in ﬁbrosis
(79%) and a higher more satisfying negative predictive value for
ruling it out (92%). Considering that the PPV may be reduced in
unselected patients with lower prevalence of advanced ﬁbrosis
(as in the cohort studied by Armstrong et al.), the actual propor-
tion of patients with advanced ﬁbrosis may be lower. Poynard
et al., when screening the general population with Fibrotest,
found a prevalence of advanced ﬁbrosis of 3% [4]. The results of
these two studies are difﬁcult to compare, as Armstrong et al.
did not provide the total number of patients screened for
increased LFTs, nor did they study NAFLD patients with normal
LFTs. However, with a rather conservative estimate of 25% of
the adult Western population having NAFLD, and only half of
them with increased LFTs, between 1% and 2% of the general pop-
ulation might have advanced ﬁbrosis due to NAFLD. These ﬁgures
are supported by the ﬁndings of Williams et al. [6] (admittedly in
a population with a high level of obesity), which used histology
instead of serum markers: 2.7% of the total population and 7%
of those with NAFLD had advanced ﬁbrosis.
Of course, these estimates will be magniﬁed in populations
biased by referral patterns to specialist care. Large studies of
selected NAFLD patients have shown a prevalence of advanced
ﬁbrosis (F3, F4 Kleiner) ranging between 17% and 27% and cirrho-
sis between 8% and 14% [18–21]. But perhaps the closest study to
the one of Armstrong et al. is the French multicentric study, men-
tioned above [15], in which patients with unexplained increases
in LFTs underwent liver biopsy. Nine out of 263 patients were
found to have cirrhosis; all nine had NASH as the underlying his-
tological diagnosis. Seventeen were found to have advanced
bridging ﬁbrosis (F3 METAVIR); all but one had NASH.
How then one can disagree with these ﬁndings of increased
prevalence and ﬁbrotic severity in patients with NAFLD and their
overall impact? Simply by stating that while cirrhosis is linked to12 vol. 56 j 23–25
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increased liver-related mortality, bridging ﬁbrosis will not kill
anyone; therefore, the high numbers of NAFLD patients with
bridging ﬁbrosis will in fact not experience liver-related morbid-
ity or mortality. While this makes sense today, tomorrow might
be different. Liver ﬁbrosis does progress, although, admittedly,
at a different pace in different individuals. Patients with bridging
ﬁbrosis have reached this stage because of active ﬁbrogenesis;
this will not stop once the diagnosis has been made, provided
that the underlying disease is still present (in fact it might even
be that with increasing age, ﬁbrosis will progress faster). There
are long-term prognostic data that support this contention, as
they show an increase in liver-related mortality or complications
of cirrhosis even in patients with bridging ﬁbrosis but without
cirrhosis. For instance, patients with NAFLD and bridging ﬁbrosis
had an independent 5.7-fold increase in liver-related mortality
over those without bridging ﬁbrosis [22]. In chronic hepatitis C,
the HALT-C trial demonstrated an association between ﬁbrosis
stages and liver-related clinical outcomes [23], already starting
at the advanced bridging ﬁbrosis stage. In a Japanese long-term
follow-up study, patients with early bridging ﬁbrosis (F2 META-
VIR) had an independent 8-fold increased risk of liver-related
death over those with no or mild ﬁbrosis (F0, F1 METAVIR)
[24]. That clearly shows that in the mid-term, bridging ﬁbrosis
is not benign. Granted, the individual predisposition to ﬁbrosis
might be different between NAFLD and HCV, in the sense that a
lesser proportion of patients with NAFLD than with HCV have
advanced ﬁbrosis. However, for those who already have bridging
ﬁbrosis, the prognosis should be the same. Micromorphometry
studies have indeed shown that for a given histological stage
and after adjustment for all main cofactors of ﬁbrosis, patients
with NAFLD have the same amount of ﬁbrosis than those with
HCV [25].
NAFLD is increasingly frequent in the general population, and
the number of those at risk of disease progression and of those
having advanced disease is clearly a concern. The next chapter
is to determine what is best to do about it, as far as screening
efforts, therapy and cost effectiveness. Fortunately, we are taking
on this new task based on a ﬁrm ground provided by these epide-
miological studies. So much the better that the labyrinth is not
built on moving sands. . .Conﬂict of interest
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